本文来自微信公众号：投中网 （ID：China-Venture），作者：王满华，题图来自：AI生成 一家创业公司想要获得上亿融资，其团队规模的下限是多少？来自挪威的Actithera给出了答案：一名员 工足矣。 近日，放射性药物生物技术公司Actithera宣布完成超额认购的A轮融资，金额达7550万美元，折合人民 币5.4亿元。 本轮融资的资本阵容堪称豪华。领投方包括德国制药巨头默克公司旗下的MVentures，以及欧洲老牌风 投Sofinnova Partners、Hadean Ventures和4BIO Capital。此外，Bioqube Ventures、Innovestor's Life Science Fund、Investinor、Surveyor Capital等欧洲各国VC，以及以色列知名风投Arkin Holdings管理的 Arkin Bio Ventures II基金也参与了本轮注资。 Actithera成立于2021年，总部位于挪威奥斯陆和马萨诸塞州剑桥，主要开发基于单克隆抗体的放射性药 物，用于肿瘤及其他难治性疾病的治疗。值得注意的是，成立4年，这家公司有且仅有一名员工，就是 创 ...

Core Viewpoint - The article highlights the rising prominence of radiopharmaceuticals, exemplified by the successful funding of Actithera, a company with a unique business model of operating with a single employee, the founder, Andreas Goutopoulos [2][3][4]. Company Summary - Actithera, founded in 2021, specializes in developing radiopharmaceuticals based on monoclonal antibodies for treating tumors and other difficult diseases. The company recently completed an oversubscribed Series A funding round of $75.5 million, equivalent to approximately 540 million RMB [3][4][6]. - The founder, Goutopoulos, has over 25 years of experience in the pharmaceutical and biotechnology sectors, previously working for Merck for 17 years. His entrepreneurial journey was inspired by breakthroughs in radiopharmaceuticals during his tenure at Merck [6][7]. - Actithera's pipeline includes four projects, with the core drug ACT017 targeting FAP, showing promising preclinical results, including an over 80% reduction in tumor volume in gastric cancer models. The company plans to initiate Phase I/II clinical trials for ACT017 in 2025 [8]. Industry Overview - The global radiopharmaceutical market was valued at approximately $7 billion in 2022 and is projected to grow at a CAGR of 18%, reaching around $18.7 billion by 2028. The capital market's interest in radiopharmaceuticals is increasing, with total financing expected to exceed $12 billion in 2024, tripling from 2020 [10][11]. - In China, 17 radiopharmaceutical companies secured over $1.3 billion in funding in 2023, indicating a growing interest from venture capitalists in this sector. Notably, Xiantong Pharmaceutical raised over 1.1 billion RMB in July 2023, setting a record for the largest single financing in the domestic radiopharmaceutical market [10][11]. - The rising demand for radiopharmaceuticals is driven by the increasing cancer incidence and the aging population, alongside supportive policies that encourage innovation in radiopharmaceutical development [12]. Entrepreneurial Trends - The article discusses the trend of "small team" entrepreneurship, exemplified by Actithera's model of operating with a single employee. This approach is seen as a response to the evolving industry landscape that emphasizes ecosystem collaboration and resource optimization [14][15]. - The success of Actithera is attributed to leveraging resources from Merck and M Ventures, suggesting that future startups may adopt similar minimalist structures while focusing on unique technological advantages and collaborative ecosystems [14][15].